ClinicaliQ Trial Snapshot
- Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma — Active Not Recruiting • Phase II • Oncology • NCT05993299.
- Gene-edited T-cell therapy trial testing safety and effectiveness in advanced synovial sarcoma and liposarcoma patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223. Conditions: Neoplasms Interventions: Letetresgene autoleucel, Cyclophosphamide, Fludarabine Lead Sponsor: USWM, LLC (dba US WorldMeds) Planned Enrollment: 7 participants